Cardiovascular complications in hemodialysis patients: current approaches to prolong and improve quality of patients’ life

F. O.  Prusskiy

doi:10.31450/ukrjnd.3(63).2019.08

F. O. Prusskiy Communal non-commercial enterprise “Kyiv municipal center of nephrology and dialysis”

DOI: https://doi.org/10.31450/ukrjnd.3(63).2019.08

Keywords: cardiovascular complications, uraemic toxins, dialysis membranes, expanded haemodialysis

Abstract

Cardiovascular complications are a leading cause of morbidity and mortality in dialysis patients. Cardiovascular mortality is more than 40% of the total mortality in this cohort of patients. Recently, there has been an increase in publications on the role of uremic toxins, including “middle molecules”, in the development and progression of cardiovascular complications in dialysis patients.

Conventional low-flux (LF) hemodialysis well removes small molecular weight uremic toxins not bound with protein. Evidence for the role of "middle molecules" in the development of many complications, including cardiovascular complications, has contributed to the emergence and development of such dialysis therapy methods as high-flux (HF) hemodialysis, hemofiltration (HF) and hemodiafiltration (HDF).

Further evolution of membrane technology has led to the development of protein-leaking membranes or super-flux or high cutoff (HCO) membranes. These membranes are capable of removing molecules in excess of the molecular weight of albumin. The use of these membranes is limited because of the risk of hypoalbuminemia.

Today, the closest approximation to the natural glomerular membrane is the so-called Middle Cut-Off (MCO) membrane. The use of MSO membranes is implemented in a new method of dialysis therapy - expanded hemodialysis (HDx). The method is defined as a treatment where diffusion and convection are conveniently combined inside a hollow-fibre dialyser equipped with an MCO membrane. A standard hemodialysis machine is used for the HDx. Increased removal of large medium molecules in HDx may lead to an improvement of clinical outcomes, including a decrease of the cardiovascular events incidence, an all-cause and cardiovascular mortality reduction in dialysis patients.

Downloads

Download data is not yet available.

References

1. US Renal Data System 2018 Annual Data Report. Volume 2 – ESRD in the United States Chapter 5: Mortality. Am J Kidney Dis. 2019;73(3S1):411-426. doi: 10.1053/j.ajkd.2018.12.016.

2. Eknoyan G, Beck GJ, Cheung AK, Daugirdas JT, Greene T et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med. 2002; 347(25):2010-9. doi: 10.1056/NEJMoa021583.

3. Naylor KL, Kim SJ, McArthur E, Garg AX, McCallum MK, Knoll GA.Mortality in Incident Maintenance Dialysis Patients Versus Incident Solid Organ Cancer Patients: A Population-Based Cohort. Am J Kidney Dis. 2019;73(6):765-776. doi: 10.1053/j.ajkd.2018.12.011.

4. US Renal Data System 2018 Annual Data Report.Volume 2 – ESRD in the United StatesChapter 8: Cardiovascular Disease in Patients with ESRD. Am J Kidney Dis. 2019;73(3S1):463–500. doi: 10.1053/j.ajkd.2018.12.020.

5. de Jager DJ, Grootendorst DC, Jager KJ, van Dijk PC, Tomas LM, Ansell D, et al. Cardiovascular and noncardiovascular mortality among patients starting dialysis. JAMA. 2009;302:1782–9. doi: 10.1001/jama.2009.1488.

6. Mavrakanas TA, Charytan DM. Cardiovascular complications in chronic dialysis patients. Curr Opin Nephrol Hypertens. 2016;25(6):536–544. doi:10.1097/MNH.0000000000000280.

7. Carrero JJ, de Jager DJ, Verduijn M, Ravani P, De Meester J et al. Cardiovascular and Noncardiovascular Mortality among Men and Women Starting Dialysis. CJASN 2011;6(7):1722-30. doi: https://doi.org/10.2215/CJN.11331210.

8. Foley RN Clinical epidemiology of cardiovascular disease in chronic kidney disease. J Ren Care. 2010;36(1):4-8. doi: 10.1111/j.1755-6686.2010.00171.x.

9. Natsionalnyi reiestr khvorykh na khronichnu khvorobu nyrok ta patsiientiv z hostrym poshkodzhenniam nyrok: 2017 rik / uklad. N.I. Kozliuk, S.S. Nikolaienko, O.O. Razvazhaieva; Derzhavna ustanova „Instytut nefrolohii NAMN Ukrainy”; hol. red. M. O. Kolesnyk. – K., 2018. – 183p. [in Ukrainian].

10. Coimbra S, do Sameiro Faria M, Miranda V, Belo L, Santos-Silva A Cardiovascular Risk Factors in End-Stage Renal Disease Patients: The Impact of Conventional Dialysis versus Online-Hemodiafiltration / Aspects in Dialysis. Edited by Ayman Karkar. Published: December 20th 2017, IntechOpen. doi: 10.5772/intechopen.70465.

11. Chirakarnjanakorn S, Navaneethan SD, Francis GS, Tang WH. Cardiovascular impact in patients undergoing maintenance hemodialysis: Clinical management considerations. Int J Cardiol. 2017;232:12–23. doi:10.1016/j.ijcard.2017.01.015.

12. Cozzolino M, Mangano M, Stucchi A, Ciceri P, Conte F, Galassi A. Cardiovascular disease in dialysis patients. Nephrol Dial Transplant. 2018;33(suppl_3):iii28–iii34. doi:10.1093/ndt/gfy174.

13. Wolley MJ, Hutchison CA. Large uremic toxins: an unsolved problem in end-stage kidney disease. Nephrol Dial Transplant. 2018;33(suppl_3):iii6–iii11. doi:10.1093/ndt/gfy179.

14. Moradi H, Sica DA, Kalantar-Zadeh K. Cardiovascular Burden Associated with Uremic Toxins in Patients with Chronic Kidney Disease. Am J Nephrol 2013;38:136-148. doi: 10.1159/000351758.

15. Ronco C, La Manna G. Expanded Hemodialysis: A New Therapy for a New Class of Membranes. Contrib Nephrol. 2017;190:124-133. doi: 10.1159/000468959.

16. Vanholder R, Van Laecke S, Glorieux G: What is new in uremic toxicity? Pediatr Nephrol 2008;23:1211-1221. doi: 10.1007/s00467-008-0762-9.

17. Vanholder R, De Smet R, Glorieux G et al. Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int. 2003;63:1934-1943. doi: 10.1046/j.1523-1755.2003.00924.x.

18. Babb AL, Ahmad S, Bergström J, Scribner BH. The middle molecule hypothesis in perspective. Am J Kidney Dis. 1981 Jul;1(1):46-50.

19. Imamović G, Canaud B, Mehmedović N, Scholz C. Principles of Haemodiafiltration: Rationale for Improved Patients’ Survival. / Advances in Hemodiafiltration Edited by Ayman Karkar. Published: September 7th 2016, IntechOpen. doi: 10.5772/63067.

20. Ronco C. Hemodiafiltration: evolution of a technique towards better dialysis care. Contrib Nephrol 2011;168:19-27. doi: 10.1159/000321741.

21. Ronco C, Crepaldi C, Brendolan A. et al. Evolution of synthetic membranes for blood purification: the case of the Polyflux family. Nephrol Dial Transplant 2003; 18(Suppl 7):10-20. doi: 10.1093/ndt/gfg1073.

22. Locatelli F, Martin-Malo A, Hannedouche T, et al. Effect of membrane permeability on survival of hemodialysis patients. J Am Soc Nephrol. 2009;20(3):645–654. doi:10.1681/ASN.2008060590.

23. Zemchenkov AYu, Gerasimchuk RP, Sabodash AB Gemodiafiltratsiya: vnimanie na ob'em (obzor literaturyi). Nefrologiya i dializ. 2014;16(1):128-138. [In Russian].

24. Peters SA, Bots ML, Canaud B, Davenport A, Grooteman MP et al. Haemodiaﬁltration and mortality in end-stage kidney disease patients: a pooled individual participant data analysis from four randomized controlled trials. Nephrol Dial Transplant. 2016;31(6):978-84. doi: 10.1093/ndt/gfv349.

25. Ward RA. Protein-leaking membranes for hemodialysis: a new class of membranes in search of an application? J Am Soc Nephrol. 2005;16:2421–2430. doi: 10.1681/ASN.2005010070.

26. BoschettideFierro A, Voigt M, Storr M, Krause B. Extended characterization of a new class of membranes for blood purifcation: the high cut-off membranes. Int J Artif Organs. 2013;36: 455–463. doi: 10.5301/ijao.5000220.

27. Ronco C. The rise of expanded hemodialysis. Blood Purif. 2017; 44(2): I–VIII. doi: 10.1159/000476012.

28. Storr M, Ward RA. Membrane innovation: closer to native kidneys. Nephrol Dial Transplant. 2018;33(suppl_3):iii22–iii27. doi:10.1093/ndt/gfy228.

29. Kirsch AH, Lyko R, Nilsson LG, Beck W, Amdahl M, Lechner P et al. Performance of hemodialysis with novel medium cut-off dialyzers. Nephrol Dial Transplant. 2017; 32 (1): 165–172. doi: 10.1093/ndt/gfw310.

30. Zickler D, Schindler R, Willy K, Martus P, Pawlak M, Storr M et al. Medium Cut-Off (MCO) Membranes Reduce Inflammation in Chronic Dialysis Patients – A Randomized Controlled Clinical Trial. PLoS One. 2017;12(1):e0169024. doi: 10.1371/journal.pone.0169024.

31. Fiore GB, Guadagni G, Lupi A, Ricci Z, Ronco C. A new semiempirical mathematical model for prediction of internal filtration in hollow fiber hemodialyzers. Blood Purif. 2006; 24: 555-568 doi: 10.1159/000097079.

32. Ronco C. Fluid mechanics and crossﬁltration in hollow-fiber hemodialyzers. Contrib Nephrol. 2007;158:34-49. doi: 10.1159/000107233.

33. Ronco C, Marchionna N, Brendolan A et al. Expanded haemodialysis: from operational mechanism to clinical results. Nephrol Dial Transplant. 2018;33(suppl_3):41-47. doi: 10.1093/ndt/gfy202.